BIND-014

BIND Therapeutics Inc (NASDAQ: BIND) is up on Thursday morning after reporting positive news at the close Wednesday. The company reported results of its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer in the "once every three weeks" treatment arm. On November 19, the...